AGENUS INC (AGEN) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $427.00K; Additional Paid in CapitalUSD $1.95B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-450.00K; Retained Earnings (Accumulated Deficit)USD $-2.14B.
- 2026-03-31: Common Stock, Value, IssuedUSD $385.00K; Additional Paid in CapitalUSD $1.92B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-437.00K; Retained Earnings (Accumulated Deficit)USD $-2.14B.
- 2025-12-31: Common Stock, Value, IssuedUSD $353.00K; Additional Paid in CapitalUSD $1.91B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-439.00K; Retained Earnings (Accumulated Deficit)USD $-2.18B.
- 2025-09-30: Common Stock, Value, IssuedUSD $329.00K; Additional Paid in CapitalUSD $1.90B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.56M; Retained Earnings (Accumulated Deficit)USD $-2.17B.
AGENUS INC Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Treasury Stock, Retired, Cost Method, Amount USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Noncontrolling Interest, Increase from Subsidiary Equity Issuance USD | Noncontrolling Interest, Decrease from Deconsolidation USD | Treasury Stock, Value USD | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD | Treasury Stock, Shares, Retired shares | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $427.00K | $1.95B | $-450.00K | $-2.14B | $-199.07M | $-205.85M | (m) | 3 month · $6.97M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $385.00K | $1.92B | $-437.00K | $-2.14B | $-221.22M | $-227.98M | (m) | 3 month · $774.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $353.00K | $1.91B | $-439.00K | $-2.18B | $-271.11M | $-277.86M | (m) | 12 month · $11.62M | (m) | 12 month · $25.04M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $329.00K | $1.90B | $-1.56M | $-2.17B | $-274.14M | $-280.87M | (m) | 3 month · $2.81M | (m) | 3 month · $25.04M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $300.00K | $1.88B | $-1.50M | $-2.24B | $-354.60M | $-336.31M | (m) | 3 month · $3.34M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $266.00K | $1.87B | $-1.47M | $-2.21B | $-341.85M | $-322.40M | (m) | 3 month · $3.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $236.00K | $1.86B | $-1.40M | $-2.18B | $-326.38M | $-306.42M | (m) | 12 month · $27.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $217.00K | $1.85B | $-1.35M | $-2.14B | $-292.34M | $-271.80M | (m) | 3 month · $9.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $211.00K | $1.83B | $-1.00M | $-2.07B | $-241.31M | $-220.84M | (m) | 3 month · $9.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $210.00K | $1.82B | $-1.07M | $-2.02B | $-201.43M | $-190.32M | (m) | 3 month · $4.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $197.00K | $1.80B | $-955.00K | $-1.96B | $-160.33M | $-148.38M | 12 month · $4.05M | 12 month · $22.35M | 12 month · $1.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $3.81M | $1.78B | $-1.03M | $-1.91B | $-129.11M | $-115.29M | (m) | 3 month · $5.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $3.67M | $1.75B | $-717.00K | $-1.85B | $-93.19M | $-76.76M | 3 month · $1.64M | 3 month · $6.04M | 3 month · $285.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $3.42M | $1.72B | $917.00K | $-1.78B | $-58.54M | $-53.11M | 3 month · $2.42M | 3 month · $5.49M | 3 month · $726.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $3.06M | $1.64B | $915.00K | $-1.71B | $-61.28M | $-54.90M | 12 month · $3.62M | 12 month · $18.39M | 12 month · $294.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $2.95M | $1.61B | $644.00K | $-1.64B | $-20.39M | $-11.84M | (m) | 3 month · $4.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $2.83M | $1.58B | $2.15M | $-1.58B | $3.42M | $13.64M | 3 month · $250.00K | 3 month · $4.62M | 3 month · $294.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $2.67M | $1.55B | $970.00K | $-1.54B | $15.72M | $27.65M | 3 month · $3.37M | 3 month · $4.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $2.57M | $1.52B | $1.49M | $-1.49B | $34.44M | $47.91M | 12 month · $1.65M | 12 month · $19.13M | 12 month · $10.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $2.48M | $1.46B | $177.00K | $-1.42B | $41.85M | $35.55M | 3 month · $157.00K | 3 month · $4.78M | 3 month · $10.00M 9 month · $10.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $2.25M | $1.35B | $260.00K | $-1.60B | $-247.12M | $-255.75M | 3 month · $1.49M | 3 month · $5.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $2.18M | $1.33B | $-1.00M | $-1.52B | $-189.66M | $-197.95M | (m) | 3 month · $3.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $1.96M | $1.26B | $2.77M | $-1.47B | $-203.67M | $-211.50M | (m) | 12 month · $10.12M | 12 month · $2.37M | (m) | (m) | (m) | (m) | (m) | 12 month · $3.15M | (m) |
| 2020-09-30 | $1.89M | $1.23B | $1.23M | $-1.43B | $-198.49M | $-206.32M | (m) | 3 month · $2.62M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $1.71M | $1.16B | $369.00K | $-1.38B | $-218.62M | $-225.96M | (m) | 3 month · $2.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $1.63M | $1.13B | $-97.00K | $-1.33B | $-195.92M | $-202.50M | (m) | 3 month · $2.40M | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $3.15M | (m) |
| 2019-12-31 | $1.38M | $1.06B | $-1.32M | $-1.28B | $-225.36M | $-231.34M | (m) | 12 month · $9.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $1.37M | $1.06B | $-1.28M | $-1.25B | $-199.69M | $-204.87M | (m) | 3 month · $3.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $1.37M | $1.05B | $-1.08M | $-1.21B | $-157.23M | $-161.61M | (m) | 3 month · $1.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $1.34M | $1.04B | $-2.22M | $-1.16B | $-116.13M | $-119.28M | (m) | 3 month · $1.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $1.20M | $1.01B | $-1.54M | $-1.18B | $-172.47M | $-174.54M | (m) | 12 month · $7.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $1.18M | $999.58M | $-1.62M | $-1.13B | $-130.41M | $-131.39M | (m) | 3 month · $1.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $1.11M | $984.19M | $-1.58M | $-1.10B | $-112.71M | $-113.09M | (m) | 3 month · $1.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $1.03M | $960.05M | $-2.71M | $-1.07B | $-113.39M | $-113.23M | (m) | 3 month · $1.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $1.02M | $951.81M | $-2.17M | $-1.03B | $-75.82M | $-75.81M | (m) | 12 month · $10.92M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $997.43K | $940.91M | $-2.06M | $-991.44M | $-51.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $996.03K | $938.41M | $-2.29M | $-954.60M | $-17.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $987.03K | $933.22M | $-1.66M | $-923.64M | $8.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $877.95K | $866.85M | $-1.53M | $-905.33M | $-39.13M | $-39.13M | (m) | 12 month · $13.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $871.15K | $858.85M | $-1.56M | $-879.21M | $-21.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $869.15K | $856.11M | $-1.66M | $-838.43M | $16.88M | (m) | (m) | (m) | (m) | (m) | $12.88K | (m) | (m) | (m) | (m) | 3.07K |
| 2016-03-31 | $865.30K | $856.07M | $-1.51M | $-810.97M | $44.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $863.91K | $851.10M | $-2.05M | $-779.19M | $70.73M | $70.73M | (m) | 12 month · $8.10M | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $3.04M | (m) |
| 2015-09-30 | $846.46K | $841.04M | $-1.33M | $-763.58M | $76.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $842.58K | $837.46M | $-658.40K | $-750.46M | $87.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 0.00 |
| 2015-03-31 | $708.36K | $756.80M | $-1.21M | $-710.05M | $46.26M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 0.00 |
| 2014-12-31 | $627.20K | $715.67M | $-1.97M | $-691.31M | $23.02M | (m) | (m) | 12 month · $4.60M | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | 0.00 |
| 2014-09-30 | $626.85K | $714.73M | $-1.16M | $-665.33M | $48.87M | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | 0.00 |
| 2014-06-30 | $626.52K | $714.09M | $135.64K | $-657.22M | $57.63M | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | 0.00 |
| 2014-03-31 | $622.31K | $711.63M | (m) | $-649.18M | $63.29M | (m) | (m) | (m) | (m) | (m) | $0.00 | $215.42K | (m) | (m) | (m) | 0.00 |
| 2014-02-20 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · 43.49K | (m) | (m) | (m) |
| 2013-12-31 | $363.91K | $644.57M | $0.00 | $-649.09M | $-4.48M | (m) | (m) | 12 month · $4.05M | (m) | (m) | $324.79K | $0.00 | (m) | (m) | (m) | 43.49K |
| 2013-09-30 | $352.72K | $640.41M | (m) | $-643.31M | $-2.88M | (m) | (m) | (m) | (m) | (m) | $-324.79K | (m) | (m) | (m) | (m) | 43.49K |
| 2013-06-30 | $286.76K | $618.77M | (m) | $-636.00M | $-17.26M | (m) | (m) | (m) | (m) | (m) | $-324.79K | (m) | (m) | (m) | (m) | 43.49K |
| 2013-03-31 | $253.46K | $596.66M | (m) | $-624.85M | $-22.68M | (m) | (m) | (m) | (m) | (m) | $-324.79K | (m) | (m) | (m) | (m) | 43.49K |
| 2012-12-31 | $246.45K | $595.92M | (m) | $-619.02M | $-17.60M | (m) | (m) | 12 month · $4.07M | (m) | (m) | $324.79K | (m) | (m) | (m) | (m) | 43.49K |
| 2012-09-30 | $246.28K | $594.92M | (m) | $-613.58M | $-13.16M | $613.60M | (m) | (m) | (m) | (m) | $324.79K | (m) | (m) | (m) | (m) | 43.49K |
| 2012-06-30 | $239.19K | $591.00M | (m) | $-607.85M | $-11.36M | $607.80M | (m) | (m) | (m) | (m) | $324.79K | (m) | (m) | (m) | (m) | 43.49K |
| 2012-03-31 | $227.88K | $584.81M | (m) | $-600.93M | $-10.63M | (m) | (m) | (m) | (m) | (m) | $324.79K | (m) | (m) | (m) | (m) | 43.49K |
| 2011-12-31 | $215.35K | $581.39M | (m) | $-607.69M | $-20.83M | (m) | (m) | 12 month · $3.34M | (m) | (m) | $324.79K | (m) | (m) | 12 month · $363.00K | (m) | 43.49K |
| 2011-09-30 | $213.80K | $585.71M | (m) | $-601.67M | $-16.07M | (m) | (m) | (m) | (m) | (m) | $324.79K | (m) | (m) | (m) | (m) | 43.49K |
| 2011-06-30 | $1.14M | $578.17M | (m) | $-596.14M | $-17.15M | (m) | (m) | (m) | (m) | (m) | $324.79K | (m) | (m) | (m) | (m) | 260.94K |
| 2010-12-31 | $186.48K | $569.85M | (m) | $-584.42M | $-14.71M | (m) | (m) | 12 month · $2.81M | (m) | (m) | $324.79K | (m) | (m) | (m) | (m) | 43.49K |
| 2009-12-31 | (m) | (m) | (m) | (m) | $-16.97M | (m) | (m) | 12 month · $3.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | $-20.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |